The gene therapy revolution: from fatal setback to living cures

Overview

Gene therapy killed Jesse Gelsinger in 1999. His death triggered FDA shutdowns and nearly ended the field.

In December 2025, Great Ormond Street and UCL published results for BE-CAR7: 82% of children with previously incurable T-cell leukemia achieved deep remission. Two-thirds remain cancer-free at three years. By early 2026, the FDA had granted Breakthrough Therapy designation to a rival off-the-shelf T-cell therapy, and TIME named researcher Waseem Qasim and first patient Alyssa Tapley among the 100 most influential people in health.

Why it matters

These cures exist, but a price tag above $400,000 and a handful of specialized hospitals decide who gets one.

Questions about this story

No questions yet — be the first to ask.

Play on this story Voices Debate Who Said What? Predict Higher or Lower Timeline Connections

Key Indicators

64%

Patients disease-free with BE-CAR7

After up to 3 years of follow-up, nearly two-thirds remain in remission without detectable cancer

82%

Deep remission rate

Patients who achieved complete molecular response, enabling stem cell transplant

$400K-$1M

Cost per CAR-T treatment

Pricing barrier limiting accessibility, especially for pediatric patients globally

FDA-approved CAR-T therapies

As of mid-2026, covering blood cancers, multiple myeloma, and primary CNS lymphoma

14 years

Emily Whitehead cancer-free

First pediatric CAR-T patient, treated April 2012, remains in complete remission

<25%

Relapsed T-ALL survival before BE-CAR7

Children who relapsed faced dismal odds before the new therapy

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Play

Exploring all sides of a story is often best achieved with Play.

Most of these play right now — no account needed. Sign up to save scores, keep a streak, and unlock Debate and Predict. Log in Sign Up

Predict 4 ways this could play out. Back the one you believe — contrarian picks score more when a scenario has a resolution date. Log in to play

People Involved

Waseem Qasim

Lead researcher on BE-CAR7 base-edited therapy; named to TIME100 Health 2026

Carl June

Pioneer of CAR-T cell therapy

Emily Whitehead

21 years old; 14 years cancer-free after becoming first pediatric CAR-T recipient

Alyssa Tapley

17 years old; nearly 4 years disease-free; named to TIME100 Health 2026

Jesse Gelsinger

Died September 17, 1999, four days after receiving experimental gene therapy

Organizations Involved

Great Ormond Street Hospital (GOSH)

Pediatric Hospital

Leading center for base-edited gene therapy trials

Britain's premier children's hospital where Alyssa Tapley became the first human to receive base-edited CAR-T cells.

University College London (UCL)

Research University

Developer of BE-CAR7 base-edited therapy

UCL scientists developed BE-CAR7, the first base-edited CAR-T therapy to reach human trials.

Novartis Pharmaceuticals

Pharmaceutical Company

Manufacturer of Kymriah, first FDA-approved CAR-T therapy

Swiss pharma giant that partnered with University of Pennsylvania to commercialize CAR-T therapy.

U.S. Food and Drug Administration

Federal regulator

Approved six CAR-T therapies; removed REMS requirements in 2025

Federal agency regulating gene therapy approvals and safety oversight.

Timeline

September 1999 March 2026

14 events Latest: March 18th, 2026 · 5 months ago Showing 8 of 14

Tap a bar to jump to that date

March 2026
Nature Paper Shows In Vivo T-Cell Engineering Works Without Cell Harvesting
Latest Research Publication

Azalea Therapeutics published research in Nature demonstrating site-specific CAR gene insertion into T-cells inside living animals, bypassing the need to extract and re-engineer cells outside the body. The result: a potential route to far cheaper, faster therapy.
March 18th, 2026
February 2026
TIME Names Qasim and Tapley to Its 2026 Health Influencer List
Recognition

TIME magazine named Professor Waseem Qasim and patient Alyssa Tapley jointly to TIME100 Health 2026, its list of the 100 most influential people in health, citing their world-first BE-CAR7 clinical trial.
February 12th, 2026
January 2026
FDA Grants Breakthrough Therapy Status to Second Off-the-Shelf T-Cell Cancer Therapy
Regulatory

Wugen's WU-CART-007, a CRISPR-edited allogeneic CAR-T therapy targeting CD7, received FDA Breakthrough Therapy designation for relapsed or refractory T-cell ALL and T-cell lymphoblastic lymphoma. In trial, the therapy achieved a 91% overall response rate and a 72.7% complete remission rate.
January 21st, 2026
December 2025
Base-Edited Therapy Results Published in NEJM
Research Publication

Great Ormond Street/UCL team publishes BE-CAR7 results: 82% deep remission, 64% disease-free at 3 years. Ten patients treated total.
December 8th, 2025
June 2025
FDA Removes CAR-T Safety Restrictions
Regulatory

FDA eliminates Risk Evaluation and Mitigation Strategy requirements for all seven approved CAR-T therapies, easing access barriers.
June 2025
December 2023
FDA Approves First CRISPR Gene Therapies
Regulatory Milestone

Casgevy and Lyfgenia approved for sickle cell disease. Casgevy is first CRISPR-based therapy approved in U.S. Priced at $2.2M and $3.1M.
December 8th, 2023
May 2022
First Human Receives Base-Edited CAR-T Therapy
World First

Alyssa Tapley receives BE-CAR7 at Great Ormond Street Hospital. First application of base-edited cells in humans. No other options remained.
May 2022
May 2021
Alyssa Tapley Diagnosed with T-Cell Leukemia
Patient Case

13-year-old from Leicestershire diagnosed with aggressive T-ALL after months of misattributed symptoms. Standard treatments fail.
May 2021
August 2017
FDA Approves Kymriah: First Gene Therapy for Cancer
Regulatory Milestone

Novartis's CAR-T therapy approved for pediatric B-cell leukemia. First gene therapy approved by FDA for any indication. List price: $475,000.
August 30th, 2017
May 2012
Emily Whitehead Cancer-Free on Seventh Birthday
Patient Outcome

After surviving cytokine storm, Emily wakes from medically induced coma. Scans show complete cancer remission. She's discharged weeks later.
May 2nd, 2012
April 2012
Emily Whitehead Becomes First Pediatric CAR-T Patient
Breakthrough

Six-year-old with terminal leukemia receives experimental CAR-T therapy at Children's Hospital of Philadelphia. Carl June's team reprograms her immune cells.
April 17th, 2012
January 2000
FDA Suspends Penn's Gene Therapy Program
Regulatory

FDA shuts down University of Pennsylvania's Institute for Human Gene Therapy after finding protocol violations and undisclosed conflicts of interest.
January 2000
September 1999
Gelsinger Declared Brain Dead; Gene Therapy Field Collapses
Crisis

Four days after treatment, Gelsinger dies from organ failure. FDA launches investigation; gene therapy trials nationwide halt.
September 17th, 1999
Jesse Gelsinger Receives Experimental Gene Therapy
Clinical Trial

18-year-old with liver disorder receives adenoviral gene therapy at University of Pennsylvania. Within 24 hours, severe immune reaction begins.
September 13th, 1999

#timeline [x-show="expanded"] { display: revert !important; opacity: 1 !important; } #timeline .timeline-toggle-btn { display: none; }

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

1999-2012

Jesse Gelsinger's Death and the Gene Therapy Dark Ages (1999-2012)

18-year-old Jesse Gelsinger died four days after receiving experimental gene therapy for a liver disorder at the University of Pennsylvania in September 1999. His severe immune reaction to the viral vector triggered organ failure and brain death. Investigations revealed undisclosed prior safety problems and financial conflicts of interest. The FDA suspended Penn's entire gene therapy program. Clinical trials nationwide halted. The field entered a 13-year reputational crisis.

Then

Gene therapy research collapsed; funding dried up; public trust evaporated; regulatory oversight intensified dramatically.

Now

Forced reforms in clinical trial safety, informed consent processes, and conflict-of-interest rules. The tragedy became the cautionary tale that shaped modern gene therapy oversight, ultimately enabling safer therapies like CAR-T.

Why this matters now

Gelsinger's death explains why BE-CAR7's success matters so profoundly—it validates that gene therapy, done right, can cure diseases once considered death sentences. The field's redemption arc hinges on proving tragedies like 1999 were preventable failures, not inherent flaws.

2012-2017

Emily Whitehead's Miracle and the CAR-T Breakthrough (2012-2017)

Six-year-old Emily Whitehead, dying from relapsed leukemia after failed chemotherapy, became the first pediatric patient to receive CAR-T therapy at Children's Hospital of Philadelphia in April 2012. Carl June's team reprogrammed her immune cells to hunt cancer. She nearly died from cytokine storm but survived. On her seventh birthday, scans showed complete remission. She left the hospital cancer-free weeks later and remains so 13 years later. Her case proved CAR-T could cure terminal childhood leukemia.

Then

Emily's cure catalyzed CAR-T clinical trials globally; patient families demanded access; pharmaceutical companies invested heavily in commercialization.

Now

Led to FDA approval of Kymriah in 2017—the first gene therapy approved for cancer. Established CAR-T as standard treatment for certain blood cancers. Six therapies now approved; over 6,000 patients treated by 2021.

Why this matters now

Emily's story directly preceded Alyssa Tapley's. Both were children with no options left who became first-in-human patients for experimental gene therapies. Emily proved CAR-T worked for B-cell cancers; Alyssa proved base editing could extend it to previously untreatable T-cell cancers.

2020-2023

CRISPR Sickle Cell Approvals: From Nobel Prize to Cure (2020-2023)

CRISPR gene editing won the Nobel Prize in Chemistry in 2020. Three years later, in December 2023, the FDA approved Casgevy—the first CRISPR-based therapy for humans—to treat sickle cell disease. Patients' blood stem cells were edited to produce fetal hemoglobin, eliminating painful vaso-occlusive crises. A second therapy, Lyfgenia, used lentiviral vectors instead of CRISPR but achieved similar results. Both priced at $2.2M-$3.1M per patient.

Then

Patients who'd suffered decades of debilitating pain experienced transformative relief; sickle cell advocates celebrated genetic diseases becoming curable.

Now

Established CRISPR as viable therapeutic platform beyond cancer. Opened regulatory pathway for other genetic diseases. Highlighted cost and accessibility as critical barriers—life-changing cures that most patients can't afford or access.

Why this matters now

The sickle cell approvals set the regulatory precedent for base-edited therapies like BE-CAR7. They proved FDA would approve CRISPR-based treatments despite gene editing's controversial history, but also demonstrated that scientific breakthroughs don't automatically translate to widespread patient access.